Kestrel Therapeutics
Developer of oncological drugs designed to treat RAS-driven cancers and bring a new therapy to cancer's frequently mutated oncogenic target. The company develops molecules active regardless of RAS iso...
Valuation
$0
Share Price
N/A
Total Raised
$20.7M
Last Round
N/A